Literature DB >> 11390015

The neuromodulatory effects of VIP/PACAP on PC-12 cells are associated with their N-terminal structures.

S Onoue1, Y Waki, Y Nagano, S Satoh, K Kashimoto.   

Abstract

ONOUE, S., WAKI, Y., NAGANO, Y., SATOH, S., KASHIMOTO, K. Neuromodulatory Effects of VIP/PACAP on PC-12 Cells Are Associated with Their N-terminal Structures. PEPTIDES xx(xx) 000-000, 200x.- The current study explored whether the differences in biological activities in PC-12 cells between vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are attributable to the sequence difference in their N-terminal portions and are correlated with the solution structures of the peptides. In the neurite outgrowth assay, N-terminal modification of VIP to PACAP-like sequences altered its effect, the activity was confirmed even at a low concentration (10(-10) M). On the contrary, N-terminal modification of PACAP 27 to VIP-like sequences reduced its activity. These relationships were also confirmed for the inhibitory effects of the peptide analogues on PC-12 cells growth at 10(-7) M. The present results combined with our previously reported data, including binding assay, support that the N-termini of VIP/PACAP plays an important role in their activities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390015     DOI: 10.1016/s0196-9781(01)00411-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

1.  Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity.

Authors:  Satomi Onoue; Kazuki Kuriyama; Atsushi Uchida; Takahiro Mizumoto; Shizuo Yamada
Journal:  Pharm Res       Date:  2011-02-02       Impact factor: 4.200

2.  Vasoactive Intestinal Peptide Decreases β-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease.

Authors:  Orhan Tansel Korkmaz; Hakan Ay; Nurgul Aytan; Isabel Carreras; Neil W Kowall; Alpaslan Dedeoglu; Nese Tuncel
Journal:  J Mol Neurosci       Date:  2018-11-29       Impact factor: 3.444

3.  Possible key residues that determine left gastric artery blood flow response to PACAP in dogs.

Authors:  Mu-Xin Wei; Ping Hu; Ping Wang; Satoru Naruse; Kiyoshi Nokihara; Victor Wray; Tsuyoshi Ozaki
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

Review 4.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

5.  Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils.

Authors:  Satomi Onoue; Keiichi Ohshima; Kazuhiro Debari; Keitatsu Koh; Seiji Shioda; Sumiko Iwasa; Kazuhisa Kashimoto; Takehiko Yajima
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

Review 6.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

Review 7.  Targeting the PAC1 Receptor for Neurological and Metabolic Disorders.

Authors:  Chenyi Liao; Mathilde P de Molliens; Severin T Schneebeli; Matthias Brewer; Gaojie Song; David Chatenet; Karen M Braas; Victor May; Jianing Li
Journal:  Curr Top Med Chem       Date:  2019       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.